Bill No. 927 amends Section 5030.1 of the Oklahoma Statutes regarding the Medicaid Drug Utilization Review Board. The bill modifies the appointment procedure for certain members of the board, specifically reducing the number of physician nominees from six to three as submitted by the Oklahoma State Medical Association. Additionally, it updates the terminology from "Pharmaceutical Association" to "Pharmacists Association" and clarifies that the member representing the pharmaceutical industry must be a resident of the state, rather than specifically the State of Oklahoma. The bill also changes the title of "vice-chair" to "vice chair" and establishes that members may serve a maximum of three three-year terms and one partial term.

The bill aims to ensure a more streamlined and representative appointment process for the Medicaid Drug Utilization Review Board, which is responsible for overseeing drug utilization programs under the Oklahoma Health Care Authority. It emphasizes the importance of geographic balance in member representation and maintains compliance with the Oklahoma Open Meeting Act and the Administrative Procedures Act. The act is set to take effect on November 1, 2025.